Medifast (NYSE:MED) Issues FY 2026 Earnings Guidance

Medifast (NYSE:MED) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of -2.750–1.55 for the period, compared to the consensus EPS estimate of -1.380. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $355.1 million. Medifast also updated its Q1 2026 guidance to -0.700–0.15 EPS.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MED. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $16.50.

Medifast Price Performance

Shares of MED stock traded up $0.01 during trading hours on Tuesday, reaching $10.78. 176,137 shares of the stock were exchanged, compared to its average volume of 223,627. The business’s fifty day moving average is $11.36 and its two-hundred day moving average is $12.34. The firm has a market capitalization of $118.48 million, a P/E ratio of 1,078.00 and a beta of 0.53. Medifast has a 12-month low of $10.10 and a 12-month high of $16.45.

Institutional Trading of Medifast

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after acquiring an additional 1,187 shares during the period. Quantbot Technologies LP purchased a new stake in Medifast in the 3rd quarter valued at $37,000. Intesa Sanpaolo Wealth Management acquired a new stake in Medifast during the 4th quarter worth $47,000. State of Wyoming purchased a new position in Medifast during the 4th quarter worth $59,000. Finally, Strs Ohio acquired a new position in Medifast in the first quarter valued at $78,000. 95.51% of the stock is owned by hedge funds and other institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.